Legislative Update: Oral Chemotherapy
Gate Way Group Contact: Deanna Hemphill
A coalition of health care providers, pharmaceutical companies, and patient organizations picked up momentum this week in an attempt to make Missouri the 28th state to require insurance coverage parity of both oral and intravenous cancer treatments. The American Legislative Exchange Council hosted members of the Missouri General Assembly, special guests, and other key stakeholders at the Capitol on Tuesday to discuss national trends in oral parity in chemotherapy medication, experiences in other states, and the relationship between innovation and access. Oklahoma Senator Greg Treat, Chair of the General Government Committee and Brian Rosen, Senior VP of Public Policy for the Leukemia & Lymphoma Society led much of the discussion.
The following day, the House Health Insurance Committee held an informational meeting to review recently released results from the actuarial study commissioned by the Missouri Legislature last year. The study was conducted by Lewis & Ellis of Overland Park, Kansas and concluded that requiring parity for oral anti-cancer medication would cost, on average, 57 cents a month for each insurance policyholder. The increase is said to be consistent with what is seen in other states that have passed parity legislation.
To date, three oral parity bills have been filed as listed below. Committee assignments are soon to come.
News & Media:
The Gate Way Group is a lobbying and association management division of Pelopidas, LLC with offices in St. Louis and Jefferson City.